Graphical Abstract Highlights d Prostate tumorigenesis caused by PTEN deletion involves loss of estrogen receptor b d ERb transcription is repressed by BMI-1, which is induced by PTEN deletion d ERb repression is needed for tumorigenesis because it enables HIF/VEGF signaling d HIF/VEGF signaling sustains BMI-1 expression, resulting in a positive feedback loop
Correspondence
In Brief A causal role for ERb in prostate cancer has not been established. Mak et al. now show that loss of ERb occurs as a consequence of prostate tumorigenesis induced by PTEN deletion, and that this loss is necessary for tumorigenesis because it enables HIF/VEGF signaling in tumor cells.
INTRODUCTION
The role of estrogen receptors (ERs) in epithelial cell biology and cancer is an emerging area of considerable biological interest and pathological relevance. In the prostate, ERb is expressed in epithelial cells, while ERa expression is confined to stromal cells (Kuiper et al., 1996; Leav et al., 2001; Thomas and Gustafsson, 2011) . The contribution of ERb to prostate cancer appears to be significant, but much remains to be learned (Christoforou et al., 2014; Dey et al., 2013) . The inverse correlation between the expression of ERb and differentiation (Gleason score) (Leav et al., 2001; Mak et al., 2010) is supported by mechanistic cell biology studies demonstrating that one function of ERb is to impede an epithelial mesenchymal transition (EMT) (Mak et al., 2010 (Mak et al., , 2013 . The mechanism involves the ability of ERb to sustain prolyl hydroxylase 2 (PHD2) expression and subsequently promote HIF-1a degradation and HIF-1-mediated EMT (Mak et al., 2013 ).
An important and timely issue is the contribution of ERb to prostate tumorigenesis. Although the loss of ERb is associated with a higher Gleason grade and more aggressive disease, a causal role for ERb in impeding the formation of aggressive tumors has not been established. There is evidence that loss of ERb can increase the incidence of poorly differentiated prostate carcinoma, but the mechanism is not known (Slusarz et al., 2012) . This problem has been obscured by the analysis of ERb knockout (BERKO) mice. These mice do not develop prostate cancer (Antal et al., 2008; Imamov et al., 2004) , although some studies have observed prostate hyperplasia in older BERKO mice (Imamov et al., 2004) . Furthermore, deletion of ERb in the FGF8b transgenic model of prostate tumorigenesis did not increase tumor incidence, a finding that has been used to discount a tumor-suppressive function for ERb (Elo et al., 2014) .
We approached the problem of the potential role of ERb in prostate tumorigenesis from a different perspective. Specifically, we hypothesized that ERb loss occurs as a consequence of tumorigenesis caused by other oncogenic mechanisms and that its loss is necessary for this tumorigenesis. To test this hypothesis, we focused on prostate tumorigenesis induced by PTEN loss for several reasons. Inactivation or loss of PTEN is one of the most common genetic lesions in prostate cancer, and its frequency increases with Gleason grade and more aggressive disease (Cairns et al., 1997; Goel et al., 2012; McMenamin et al., 1999) . Given that ERb loss also increases with de-differentiated, aggressive disease (Mak et al., 2010) , these observations suggest a causal relationship between loss of PTEN and loss of ERb that may be significant for prostate tumorigenesis. The results presented in this study validate this hypothesis and provide a mechanism for how PTEN loss results in the transcriptional repression of ERb that involves BMI-1, an oncogene that regulates cell proliferation and senescence through the ink4a locus (Jacobs et al., 1999) and has been implicated in prostate tumorigenesis (Lukacs et al., 2010) . Importantly, we also establish that the loss of ERb is necessary for tumorigenesis caused by PTEN loss because it enables autocrine VEGF signaling, which has been implicated in the genesis of several cancers including prostate (reviewed in Goel and Mercurio [2013] ).
RESULTS

ERb Is Targeted for Repression in Prostate Tumorigenesis Induced by PTEN Loss
To assess the potential relationship between ERb and PTEN, we evaluated ERb expression in a transgenic model of prostate tumorigenesis mice induced by PTEN deletion (Pten loxp / loxp ; PB-Cre + [referred to as Pten pc À/À ]). Prostate-specific deletion of PTEN results in tumors that are invasive and aggressive (Wang et al., 2003) . The normal glandular features of the wildtype prostates (control) and tumor formation in age-matched Pten pc À/À prostates are shown in Figure 1A . PTEN expression is apparent in wild-type prostates but absent in Pten pc À/À mice ( Figure 1B) . Importantly, ERb expression is lost in Pten pc À/À mice, whereas the age-matched wild-type prostates exhibit ERb expression ( Figure 1C ). We also observed that PTEN and ERb expression correlate in human prostate tumors based on analysis of the cBioportal database ( Figure 1D ; Table S1 ). High Gleason grade tumors (primary Gleason grade 5) exhibit uniform loss of PTEN and ERb (Cairns et al., 1997; Mak et al., 2010) . Gleason grade 3 tumors are interesting in this regard because these tumors are characterized by heterogeneity in PTEN expression (McMenamin et al., 1999) . Indeed, we quantified PTEN and ERb mRNA expression in grade 3 tumors and observed a correlation between PTEN and ERb expression ( Figure 1E ).
To investigate the relationship between ERb and PTEN further, we depleted PTEN in PNT1a cells, an immortalized prostate epithelial cell line (Berthon et al., 1995) . Depletion of PTEN caused an EMT consistent with previous reports Song et al., 2009) , and it also resulted in a decrease in ERb mRNA and protein expression compared to control cells, indicating that PTEN regulates ERb expression ( Figure 1F ). In contrast, ERb does not appear to impact PTEN expression because depletion of ERb did not alter PTEN levels ( Figure 1G ). Furthermore, two physiological ligands of ERb (3b-Adiol and 17b-estradiol:E2) did not affect PTEN expression ( Figure 1G ). Interestingly, both a PI3K inhibitor (wortmannin) and Akt inhibitor (Akt Inhibitor VIII) reversed the mesenchymal phenotypes of PTEN-depleted PNT1a cells to an epithelial phenotype with a concomitant restoration of ERb expression ( Figure 1H ).
To support a functional link between PTEN and ERb expression, we examined the effect of expressing ERb in PTENdepleted PNT1a cells. The mesenchymal morphology of PTEN-depleted cells reverted to an epithelial morphology in response to expression of HA-ERb with a concomitant decrease in mesenchymal markers (N-cadherin and vimentin) ( Figure 2A ). We also assessed the tumor-suppressive activity of ERb in the context of PTEN by injecting control cells, PTEN-depleted cells, and PTEN-depleted cells that express ERb into nude mice. Control cells did not form tumors after 9 weeks, whereas 71% of mice injected with PTEN-depleted cells had tumors at this time ( Figure 2B ). More importantly, tumor formation was greatly reduced (12% of mice had tumors) when mice were injected with PTEN-depleted cells expressing HA-ERb ( Figure 2B ). This observation was substantiated by expressing ERb in PC3-M cells, a highly tumorigenic, PTEN-prostate cancer cell line (Kozlowski et al., 1984) that expresses low levels of ERb ( Figure 2C ).
Indeed, ERb expression dramatically reduced the ability of these cells to form tumors ( Figure 2C ).
BMI-1 Is a Transcriptional Repressor of ERb
To define the mechanism by which loss of PTEN diminishes ERb expression, we focused on BMI-1, the key regulatory component of the polycomb repressive complex-1 that modulates chromatin structure and represses the transcription of a number of genes (Cao et al., 2005; Jacobs et al., 1999; Miyazaki et al., 2008) , for several reasons. BMI-1 has been implicated in prostate hyperplasia and tumorigenesis (Lukacs et al., 2010; van Leenders et al., 2007) . We also found that expression of BMI-1 in ERb-expressing PTEN-depleted cells promoted tumor formation ( Figure 2C ). Furthermore, PTEN loss induces BMI-1 expression (Goel et al., 2012) , as evident in PNT1a cells ( Figure 2D ). The ability of both wortmannin and Akt Inhibitor VIII to attenuate BMI-1 expression in shPTEN cells supports our previous finding on their ability to restore ERb expression in these cells (Figure 2E) . For these reasons, we evaluated the possibility that BMI-1 represses ERb. Expression of BMI-1 in PNT1a cells suppressed ERb compared to control cells ( Figure 2F ). Conversely, we depleted BMI-1 in PC3-M cells and observed an induction of ERb expression compared to the control ( Figure 2G ). We also observed that 17b-estradiol (E2) had no effect on the expression of BMI-1 on PTEN-depleted cells, suggesting that ERa does not regulate BMI-1 ( Figure 2H ). The multiple bands observed in the BMI-1 immunoblots may represent phosphorylated forms of the protein (Nacerddine et al., 2012) .
The inverse functional relationship between BMI-1 and ERb prompted us to test the possibility that BMI-1 is a transcriptional repressor of ERb. Therefore, we performed chromatin immunoprecipitation (ChIP) analysis on the ERb promoter to assess BMI-1 binding. We examined eight regions within the 3 kb spanning from +331 to À2,996 base pairs and detected one major BMI-1 binding locus in region 1 proximal to the transcription start site ( Figure 2I ; Figure S1A ). The impact of BMI-1 on ERb promoter activity was evaluated by expressing luciferase reporter constructs containing two regions of the promoter (region 1 and regions 1 and 2) in control and BMI-1-depleted PC3-M cells. Diminishing BMI-1 expression resulted in a significant increase in luciferase activity in both constructs compared to the control ( Figure 2J ). Moreover, this activity was concentrated in region 1, supporting our ChIP data. Given that ERb expression is regulated by two promoters, 0N and 0K (Hirata et al., 2001) , we sought to determine which promoter is utilized by BMI-1 to exert its repressive function. The BMI-1 binding locus of region 1 in our ChIP assays lined up perfectly within the 0N promoter, but not within the 0K promoter ( Figure S1B ). These data indicate that ERb transcription is repressed by BMI-1 on the 0N promoter.
Role of ERb Repression in Prostate Tumorigenesis
The critical issue that arises from the foregoing observations is why ERb repression is important for prostate tumorigenesis induced by PTEN loss (see Figure 1A ). Previously, we reported that loss of ERb stabilizes HIF-1a and enables autocrine VEGF signaling in prostate cancer cells (Mak et al., 2010) . This finding is relevant because autocrine VEGF signaling has emerged as an important component of tumorigenesis ( 2013). Of particular relevance, we reported that autocrine VEGF signaling results in the enhancement of BMI-1 expression by a mechanism that involves Neuropilin-2 (NRP2) and Gli-1 (Goel et al., 2012) . Together, these observations support the hypothesis that ERb repression is important for prostate tumorigenesis induced by PTEN loss because it enables autocrine VEGF signaling via HIF-1a stabilization that sustains BMI-1 expression. Initially, we assessed HIF-1a and VEGF expression in wild-type and Pten pc À/À prostates. Deletion of PTEN induced the expression of HIF-1a, VEGF, as well as BMI-1 ( Figures 3A-3C) , in tumor cells. This observation is supported by the analysis of PTENdepleted PNT1a cells, which express high levels of HIF-1a, VEGF-A, and BMI-1 compared to control cells (shGFP) (Figure 3D) . To demonstrate that the increase in VEGF and BMI-1 expression observed in response to PTEN deletion is dependent on ERb repression, we expressed ERb in PTEN-depleted PNT1a cells and observed a reduction in VEGF and BMI-1 expression compared to controls ( Figure 3E ). The results reported so far indicate that PTEN loss results in the BMI-1-mediated repression of ERb and that repression of ERb enables VEGF signaling that sustains BMI-1 expression. In essence, the data reveal a positive feedback loop that functions to maintain BMI-1 expression and is activated in response to PTEN loss. This hypothesis infers that loss of ERb should induce BMI-1 expression by a mechanism that involves HIF-1/VEGF signaling. Indeed, depletion of ERb in PNT1a cells induced HIF-1a, VEGF-A, and BMI-1 expression compared to the controls ( Figure 4A ). We also observed an induction of NRP2 in ERb-depleted cells with a concomitant increase in BMI-1 (Figure S2) . Similar results were obtained by depleting PHD2, which is sustained by ERb (Mak et al., 2013 ; Figure 4B ). The PHD2depleted cells also had high expression levels of N-cadherin and vimentin compared to the control cells, supporting our previous observation that loss of PHD2 induced an EMT in PNT1a cells (Mak et al., 2013) . To establish a causal role for HIF-1a in regulating BMI-1 expression, we knocked down HIF-1a in ERb-depleted cells and observed a substantial decrease in VEGF-A and BMI-1 expression compared to ERb-depleted cells alone ( Figure 4C ). These expression differences also were manifested in cell morphology. Control (shGFP) and shERb/shHIF-1a cells exhibited an epithelial morphology compared to the mesenchymal morphology of shERb/shGFP cells ( Figure 4C ). Based on these data, the possibility existed that BMI-1 is a HIF-1a target gene. However, promoter activity analyses did not support this possibility (data not shown). For this reason, we focused on the role of VEGF-A signaling in regulating BMI-1 in the context of ERb. Specifically, knocking down VEGF-A in ERb-depleted cells attenuated BMI-1 expression and induced an epithelial morphology ( Figure 4D ). Subsequently, we analyzed the prostates of BERKO mice to assess the impact of ERb loss on HIF-1a, VEGF, and BMI-1 expression. Ventral prostates of wild-type mice (control) exhibited normal glandular structure with ERb expression in epithelial cells and undetectable HIF-1a and BMI-1 and very low VEGF-A expression ( Figure 4E ). In contrast, BERKO mice of the same age and genetic background exhibited hyperplasia and decreased epithelial differentiation with high HIF-1a, VEGF-A, and BMI-1 expression in the absence of ERb (Figure 4E) . Interestingly, both control and BERKO prostates exhibited a similar intensity of PTEN staining ( Figure 4E ). Five BERKO mice and their control counterparts were examined with similar findings. These observations were substantiated by the observation that a negative correlation between ERb and BMI-1 expression exists in a cohort of 87 human prostate tumors, based on analysis of the cBioportal database (Figures 4F; Table S2 ).
DISCUSSION
This study provides insight into the role of ERb in prostate tumorigenesis and the mechanisms that regulate its expression. First and foremost, we demonstrate that prostate tumorigenesis caused by PTEN deletion involves BMI-1-mediated repression of ERb and that repression of ERb enables HIF-1/VEGF signaling that sustains BMI-1 expression. These findings should help to clarify the issue of why prostate cancer has not been observed in BERKO mice. Specifically, we argue that loss of ERb is not sufficient to promote tumorigenesis in the absence of an oncogenic stimulus, despite the fact that BMI-1 expression is increased. This hypothesis is consistent with the report that BMI-1 inhibition slows the growth of PTEN-deletion-induced prostate cancer, but it does not prevent tumorigenesis (Lukacs et al., 2010) . In fact, we found that BERKO prostates retain PTEN expression. A reasonable hypothesis going forward is that PTEN loss involves additional events, such as the enhancement of PI3K/Akt signaling, that are essential for tumorigenesis (Worby and Dixon, 2014) .
The fact that ERb expression is lost during tumorigenesis caused by PTEN deletion is significant and relevant to other studies that have investigated the consequences of ERb loss in the prostate. Specifically, it was reported recently that deletion of ERb in the FGF8b transgenic model of prostate tumorigenesis did not increase tumor incidence (Elo et al., 2014) . Although the authors discounted a tumor-suppressive role for ERb based on these data, this conclusion should be tempered by the likely possibility that FGF8b-mediated tumorigenesis involves repression of ERb, similar to our finding with prostate tumorigenesis caused by PTEN deletion. For this reason, deleting ERb in either the FGF8b or PTEN models would not be expected to increase tumor incidence.
This study also addresses the mechanism by which ERb is regulated in prostate cancer. Several studies have observed an inverse correlation between ERb expression and differentiation (Gleason grade), but the mechanisms that contribute to the loss of ERb in high-grade cancers are not well understood. Some reports indicated that hypermethylation of the ERb promoter is associated with loss of expression (Lau et al., 2000; Zhu et al., 2004) . Although our data do not discount the contribution of promoter methylation, compelling evidence now exists that BMI-1 expression correlates with Gleason grade and that BMI-1 is induced as a direct consequence of PTEN loss or inactivation (Goel et al., 2012) . Moreover, we detected an inverse correlation between ERb and BMI-1 in a cohort of human prostate tumors. These observations, coupled with our demonstration that BMI-1 can bind to the ERb 0N promoter and repress transcription, strongly implicate BMI-1 in the repression of ERb in prostate cancer. Paradoxically, ERb is expressed in prostate cancer metastases (Fixemer et al., 2003; Lai et al., 2004) . It is tempting to speculate that this ERb expression is regulated by the 0K promoter, which is not repressed by BMI-1. From a different perspective, these findings add a new dimension to our understanding of how BMI-1 contributes to prostate tumorigenesis. Although BMI-1 also has been reported to suppress PTEN expression in nasopharyngeal epithelial cells (Song et al., 2009 ), we did not observe this phenomenon in the prostate epithelial and carcinoma cells that we analyzed.
Our finding that ERb functions to suppress BMI-1 is significant because it forms the basis of our hypothesis that a positive feedback loop exists that maintains BMI-1 expression. Although ERb has been implicated as a gatekeeper that impedes prostate tumorigenesis (Dey et al., 2013; Hussain et al., 2012; Slusarz et al., 2012) , the mechanisms involved are not known. Clearly, its ability to repress BMI-1 is one such mechanism. Moreover, these findings add to our understanding of how BMI-1 is regulated in prostate cancer. Previous work by our group demonstrated that autocrine VEGF signaling in tumor cells sustains BMI-1 expression (Goel et al., 2012) , but it was not apparent that this pathway is subject to inhibition by ERb. As mentioned, autocrine VEGF signaling in tumor cells is emerging as an (C) HIF-1a expression was diminished in ERb-depleted PNT1a cells using shRNA, and the impact on cell morphology and expression of HIF-1a, VEGF-A, and BMI-1 was determined. Scale bar, 50 mm. (D) VEGF-A expression was diminished in ERb-depleted PNT1a cells using shRNA, and the impact on cell morphology (phase contrast images) and expression of VEGF and BMI-1 was determined by immunoblotting. (E) H&E staining of ventral prostates from 10-month-old wild-type (control) and BERKO mice. Arrows indicate areas of hyperplasia. These tissues were stained for ERb, HIF-1a, VEGF-A, BMI-1, and PTEN and analyzed by immunofluorescence microscopy. Scale bar, 50 mm.
(F) An inverse correlation between BMI-1 and ERb in a cohort of 87 prostate tumors was determined from analysis of the cBioportal database ( Figure S1B ; Taylor et al., 2010) . (G) Schematic summares the major conclusions of the study. See also Figure S2 and Table S2 .
important mechanism that sustains the function of cancer stem cells and promotes tumor initiation, as evidenced by data obtained from several different cancers including prostate (Goel and Mercurio, 2013) . Moreover, the ability of VEGF signaling to sustain BMI-1 expression accounts for how this pathway contributes to de-differentiation and tumorigenesis. The ability of ERb to promote HIF-1a degradation and, consequently, repress VEGF expression and signaling provides a mechanism for suppressing the tumorigenic potential of BMI-1. Indeed, the induction of HIF-1a, VEGF, and BMI-1 expression in BERKO mice, in concert with the inverse correlation observed between ERb and these molecules in human prostate tumors, provides support for this hypothesis. These findings also reinforce the hypothesis that loss of ERb in prostate cancer mimics hypoxia by enabling HIF-1a/VEGF signaling. Interestingly, a tumor-suppressive function for ERb in breast cancer was reported recently (Yuan et al., 2014) .
In summary, the data we report advance our understanding of how ERb functions in prostate cancer as both a gatekeeper of epithelial differentiation and tumorigenesis and a target of oncogenic stimuli, as depicted in Figure 4G .
EXPERIMENTAL PROCEDURES
Cells and Reagents
PNT1a cells were obtained from M. Littmann (Baylor College of Medicine). The human prostate cancer cell line LNCaP was obtained from American Type Culture Collection (ATCC). PC3-M cells were obtained from R.C. Bergan (Northwestern University). 3b-androstane-diol (3b-adiol) and 17b-estradiol (E2) experiments were performed by incubating cells with 3b-adiol (5 mM; Sigma-Aldrich) or E2 (10 nM; Sigma-Aldrich) for 2 to 3 days. Wortmannin and Akt inhibitor VIII were obtained from Calbiochem. Cells were incubated with these inhibitors (5 mM) for 18À20 hr prior to subsequent analyses. The generation of ERb and PHD2-ablated PNT1a cells using small hairpin RNAs (shRNAs) has been described previously (Mak et al., 2013) . Lentiviruses (pLKO.1) containing BMI-1 shRNA oligonucleotides (TRCN0000020154, TRCN0000020156, and TRCN0000012565), VEGF-A shRNA oligonucleotides (TRCN0000003343), HIF-1a shRNA (TRCN0000054449), PTEN shRNA (TRCN0000028989 and TRCN0000028990), or pLKO-shGFP control were purchased from Open Biosystems and used to infect cells following standard protocols. Stable cell transfectants were generated by puromycin or hygromycin selection (0.5 mg/ml for PNT1a and 2 mg/ml for PC3-M cells). The resultant ERb-, PHD2-, BMI-1-, HIF-1a-, or VEGF-A-ablated cells were used for subsequent experiments. A lentiviral plasmid (FUGW) expressing BMI-1 and the control vector (FUGW) carrying the empty vector (EV) were obtained from Addgene.
Biochemical Analyses
For immunoblotting, the following Abs were used: ERb and PTEN (GeneTex), BMI-1 (Cell Signaling Technology), vimentin (Dako), HIF-1a (Novus Biologicals), PHD2 (Abcam), and a-tubulin and b-actin (Sigma-Aldrich). Immune complexes were detected using enhanced chemiluminescence (ECL) (Pierce). For quantitative real-time RT-PCR (qPCR), total RNA was extracted from cells using the TRI reagent (Sigma-Aldrich) and was reverse transcribed using reverse transcription reagents (Applied Biosystems), and then analyzed by SYBR Green Master (Rox) (Roche) using a real-time PCR system (ABI PRISM 7900HT Sequence Detection System, PE Biosystems). The expression of target genes was normalized to 18 s RNA and analyzed by the comparative cycle threshold method (DDCt).
ChIP was performed using the ChIP-IT Express kit (53008, Active Motif). Briefly, the attached cells were cross-linked using 1% formaldehyde for 15 min at room temperature (RT) with rotation. Subsequent steps for ChIP analysis were performed according to the manufacturer's protocol. For chro-matin precipitation, 3 mg BMI-1 antibody (Cell Signaling Technology) or human isotype IgG (16-4301-81, eBioscience) was used. End-point real-time PCR was performed using the primer pairs listed in Figure S1E . For luciferase assays, PC3-M cells were transfected with the desired plasmids and the Renilla luciferase construct to normalize for transfection efficiency. Luciferase assays were performed using Dual Glo luciferase assay system (Promega). Relative luciferase activity was calculated as the ratio of firefly luciferase to Renilla luciferase activity.
Xenograft Experiments
Cells were mixed with Matrigel (30%) and injected subcutaneously into nu/nu mice (6 weeks old, Jackson ImmunoResearch Laboratories) using a single dose as follows: PNT1a (10 6 ) and PC3-M (10 5 ). Animals were monitored three times per week for tumor formation by palpation. All animal experiments were in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee at the University of Massachusetts Medical School.
Transgenic Mice
ERb knockout (BERKO) mice were generated by the Korach laboratory (Krege et al., 1998) and were purchased from The Jackson Laboratory. The knockout allele was maintained on a C57BL/6 background. The mice used in these studies were 10 months old. Sections from these prostates and age-matched controls were processed for immunostaining as described below. A similar approach was used for specimens obtained from prostate tissue obtained from Pten loxp / loxp ; PB-Cre + mice (prostate cancer) and age-matched Pten +/+ ; PB-Cre + mice (normal prostate) (Hü bner et al., 2012) .
Immunostaining
Murine prostate specimens from transgenic mice (see above) and human prostate cancer specimens, which were obtained from the Tissue Bank at the University of Massachusetts Medical School, were fixed in paraformaldehyde (4%), embedded in paraffin, sectioned (5 mM), and used for H&E and immunofluorescence staining. Immunofluorescence staining was conducted according to the manufacturer's instructions (Invitrogen and Life Sciences). After antigen unmasking, the specimens were incubated in 10% serum in PBS for 30 min, washed for 3 min in PBST, and incubated with rabbit polyclonal ERb antibody (GTX 112927, GeneTex) or rabbit BMI-1 mAb (5856S, Cell Signaling Technology) overnight at 4 C. The slides were washed 5 min with PBST and incubated 45 min in a dark chamber with the fluorochrome-conjugated secondary antibody (goat anti-rabbit conjugated Alexa Fluor 488, A-11008, Life Sciences). Slides were washed and counterstained in the dark with DAPI (Invitrogen) for 10 min, washed with three changes of PBST, and mounted under coverslips with aqueous mounting medium (Thermo Electron). Results were analyzed with an LSM 710 Meta confocal microscope (Carl Zeiss).
Statistical Analysis
Data are presented as the mean from three separate experiments ± SD. The Student's t test was used to determine the significance of independent experiments. The criterion p < 0.05 was used to determine statistical significance. 
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